AUTLAutolus Therapeutics plc
$1.77+18% 1Y
$1.77
$1.2152 weeks$2.54
Is the business good?
Mixed
1 neutral, 3 without dataMargins steady. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 yearsStablederived
Margins have held roughly steady, a stable cost structure.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is AUTL?
Autolus Therapeutics plc keeps −211% of every revenue dollar as operating profit, against −77% for the median Biotechnology name.
−211%
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Share count, year on year
- +0.01%
Share count, year on year · flat: no meaningful dilution
- R&D as % of revenue
- 96%
R&D as % of revenue
- Gross margin
- 16%
Gross margin
| Year | Operating margin |
|---|---|
| FY2023 | −10583% |
| FY2024 | −2386% |
| FY2025 | −359% |
Details›
- Gross margin12 months to Q2 2026
- 16%
- Operating margin12 months to Q2 2026
- −211%
- Net margin12 months to Q2 2026
- −239%
- Free cash flow margin
- −200%
- R&D as % of revenue
- 96%
- Revenue, trailing twelve months
- $117M
- Free cash flow, trailing twelve months
- −$235M
- Net income, trailing twelve months
- −$280M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.